Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Fineline Cube May 15, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company Deals

Schrödinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates

Fineline Cube Nov 13, 2024

New York-based Schrödinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of mRNA Vaccine SYS6026

Fineline Cube Nov 13, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...

Policy / Regulatory

NHSA and MoF Announce Medical Insurance Fund Prepayment Initiative to Aid Healthcare Institutions

Fineline Cube Nov 12, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued...

Company

InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials

Fineline Cube Nov 12, 2024

Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the...

Company Deals

Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%

Fineline Cube Nov 12, 2024

Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ:...

Company

GenScript Biotech Expands in Australia with New Sydney Operations and Logistics Center

Fineline Cube Nov 12, 2024

GenScript Biotech Corporation (HKG: 1548), a leading Chinese biotechnology company, has announced the establishment of...

Company Deals

Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies

Fineline Cube Nov 12, 2024

China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A...

Company Deals

Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences

Fineline Cube Nov 12, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its...

Company Drug

Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024

Fineline Cube Nov 12, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation...

Company Drug

J&J’s Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease

Fineline Cube Nov 12, 2024

US-based pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received...

Company Drug

Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Nov 12, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE...

Company Drug

Cutia Therapeutics’ CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment

Fineline Cube Nov 12, 2024

Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced that its CU-10201, a...

Company Drug

BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC

Fineline Cube Nov 12, 2024

BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest...

Company Drug

Abbisko Therapeutics’ Pimicotinib Meets Primary Endpoint in Phase III MANEUVER Study for TGCT

Fineline Cube Nov 12, 2024

hanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has revealed positive top-line results from the...

Company Drug

ETERN Therapeutics’ ETS-006 Receives FDA Orphan Drug Designation for Pleural Mesothelioma

Fineline Cube Nov 12, 2024

ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced that it has received...

Company Drug

Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD

Fineline Cube Nov 12, 2024

Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...

Company

Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline

Fineline Cube Nov 11, 2024

US generics giant Viatris (NASDAQ: VTRS) has published its financial report for the third quarter...

Company

Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies

Fineline Cube Nov 11, 2024

Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results...

Company

GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership

Fineline Cube Nov 11, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn...

Company Deals

ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation

Fineline Cube Nov 11, 2024

ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed...

Posts pagination

1 … 269 270 271 … 666

Recent updates

  • Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
  • Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”

Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.